Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycythemia Vera 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Carcinoma, Hepatocellular 6Thrombocythemia, Essential 5Neoplasms 3Melanoma 3Skin Neoplasms 2Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Solid Cancers 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm of Uncertain Malignant Potential 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis D 1Hepatitis C 1Hepatitis B, Chronic 1Hepatitis B 1Hemangiosarcoma 1

Interventions

Ribavirin 5ledipasvir, sofosbuvir drug combination 3sofosbuvir-velpatasvir drug combination 2elbasvir-grazoprevir drug combination 2Sorafenib 2Sofosbuvir 2Chromatography, High Pressure Liquid 2tremelimumab 1telaprevir 1rocakinogene sifuplasmid 1pembrolizumab 1peginterferon alfa-2a 1navitoclax 1menatetrenone 1ledipasvir 1hepatitis C immune globulin, human 1grazoprevir 1elbasvir 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Patient Navigation 1Medical Marijuana 1Mass Screening 1Introns 1Infliximab 1Immunoglobulin G 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatitis C × peginterferon alfa-2a × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡